Exposure to strong static magnetic field slows the growth of human cancer cells in vitro.
Proposals to enhance the amount of radiation dose delivered to small tumors with radioimmunotherapy by constraining emitted electrons with very strong homogeneous static magnetic fields has renewed interest in the cellular effects of prolonged exposures to such fields. Past investigations have not studied the effects on tumor cell growth of lengthy exposures to very high magnetic fields. Three malignant human cell lines, HTB 63 (melanoma), HTB 77 IP3 (ovarian carcinoma), and CCL 86 (lymphoma: Raji cells), were exposed to a 7 Tesla uniform static magnetic field for 64 hours. Following exposure, the number of viable cells in each group was determined. In addition, multicycle flow cytometry was performed on all cell lines, and pulsed-field electrophoresis was performed solely on Raji cells to investigate changes in cell cycle patterns and the possibility of DNA fragmentation induced by the magnetic field. A 64 h exposure to the magnetic field produced a reduction in viable cell number in each of the three cell lines. Reductions of 19.04 +/- 7.32%, 22.06 +/- 6.19%, and 40.68 +/- 8.31% were measured for the melanoma, ovarian carcinoma, and lymphoma cell lines, respectively, vs. control groups not exposed to the magnetic field. Multicycle flow cytometry revealed that the cell cycle was largely unaltered. Pulsed-field electrophoresis analysis revealed no increase in DNA breaks related to magnetic field exposure. In conclusion, prolonged exposure to a very strong magnetic field appeared to inhibit the growth of three human tumor cell lines in vitro. The mechanism underlying this effect has not, as yet, been identified, although alteration of cell growth cycle and gross fragmentation of DNA have been excluded as possible contributory factors. Future investigations of this phenomenon may have a significant impact on the future understanding and treatment of cancer.
University of Michigan Medical Center, Department of Internal Medicine, Ann Arbor, USA.
R R
RR
Raylman
A C
AC
Clavo
R L
RL
Wahl
D002277:Carcinoma / Q000473:pathology* / Q000628:therapy; D002453:Cell Cycle; D002455:Cell Division; D002470:Cell Survival; D053938:DNA Fragmentation; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D005434:Flow Cytometry; D016193:G1 Phase; D006801:Humans; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy; D008280:Magnetics / Q000627:therapeutic use; D008545:Melanoma / Q000473:pathology* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D016196:S Phase; D014407:Tumor Cells, Cultured